Press Releases

BIOMS PLANS RELAPSING-REMITTING MULTIPLE SCLEROSIS TRIAL

-MBP8298 to be tested in a second major MS patient population-

Edmonton, Alberta, March 13, 2006 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it is expanding the clinical development program for its lead drug candidate MBP8298. The drug is currently undergoing an international pivotal phase II/III clinical trial with secondary progressive MS patients (SPMS). BioMS now plans to initiate a clinical trial for MBP8298 in relapsing-remitting MS (RRMS) patients in the second half of 2006.

“We have good scientific rationale to believe that MBP8298 has the potential to provide a benefit to MS patients at any stage of the disease,” said Kevin Giese, President and CEO of BioMS Medical. “If our drug is able to show efficacy in relapsing-remitting MS patients as it has in trials with secondary progressive MS patients, then it would represent a great benefit for this equally large MS population.”

MS affects approximately 2.5 million people worldwide, of which 40-45% have RRMS and 40-45% have SPMS.

BioMS Medical recently announced study results demonstrating that MBP8298 delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. These findings will be presented at the 58th Annual Meeting of the American Academy of Neurology on April 4, 2006 in San Diego, CA.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.